enVVeno Medical Corporation’s SEC filings document a medical device issuer developing replacement venous valve technologies for severe deep chronic venous insufficiency. Recent 8-K reports record FDA-related events for the enVVe System and VenoValve, including IDE authorization for the TAVVE pivotal study and disclosures related to VenoValve PMA review outcomes.
The company’s filings also cover capital structure and governance matters, including a one-for-35 reverse stock split, Nasdaq minimum-bid compliance, an at-the-market common stock offering program, annual meeting voting results, director elections, executive-compensation advisory votes, auditor ratification, and proxy materials describing shareholder proposals and regulatory context for the device programs.
enVVeno Medical Corporation received a Schedule 13G filing showing that investor Braeden Lichti beneficially owns 33,151 shares of common stock, representing 5.05% of the company. This total includes 13,022 shares over which he has sole voting and dispositive power.
Lichti also shares voting and dispositive power over 20,129 shares held through Northstrive Fund II LP, which separately reports beneficial ownership of those 20,129 shares, or 3.07% of the common stock. Percentages are based on 655,606 shares outstanding as of January 20, 2026.
enVVeno Medical Corporation reported that as of December 31, 2025, it held a cash and investments balance of approximately $28 million, highlighting its available liquidity at year end. The company also announced that it has regained compliance with the minimum bid price requirement and all other criteria for continued listing on The NASDAQ Stock Market, removing an immediate risk to its exchange listing. The announcement was made through a press release furnished as an exhibit to this report.
enVVeno Medical Corporation implemented a one-for-thirty-five reverse stock split of its common stock, effective January 20, 2026. Every 35 previously issued and outstanding shares were automatically combined into one share, with no change to the par value.
No fractional shares were issued; any fractional positions were rounded up to the nearest whole share. The number of common shares outstanding decreased from 22,946,223 to 655,606, while authorized common shares remain at 250,000,000.
The company proportionally adjusted outstanding stock options and warrants so that share amounts decreased by a factor of 35 and exercise prices increased by a factor of 35, preserving their overall economic value. The stock now trades on a reverse split-adjusted basis on Nasdaq under the symbol NVNO.
enVVeno Medical Corp’s chief executive officer and director, Robert A. Berman, reported insider transactions involving both common stock and equity awards. The Form 4 discloses a disposition of 22,236 shares of common stock, and a related filing shows changes in his derivative holdings.
In addition, 200,000 restricted stock units that were granted to him on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan were voluntarily surrendered and cancelled on December 16, 2025. These units were subject to vesting based on specified performance milestones, which were not achieved, so the unvested awards were given up and no longer provide rights to common shares.
enVVeno Medical Corp executive Hamed Alavi, the company’s Chief Technology Officer, reported a change in his equity holdings. A Form 4 filing shows that 50,000 restricted stock units were surrendered and cancelled at a price of $0. These units were originally issued on November 30, 2021 under the Amended and Restated 2016 Omnibus Incentive Plan and were subject to performance-based vesting conditions.
The filing explains that the specified performance milestones were not achieved, and therefore the unvested restricted stock units were voluntarily cancelled. Following this transaction, the number of derivative securities of this type beneficially owned by Alavi is reported as 0.
enVVeno Medical Corp executive reports cancellation of equity award. SVP & Chief Medical Officer Dr. Marc Glickman filed a beneficial ownership report showing that 100,000 restricted stock units were surrendered and cancelled after specified performance milestones tied to the award were not achieved. The units were originally granted on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan and a Restricted Stock Unit Agreement, and had been scheduled to expire on November 30, 2031. Following this transaction dated December 16, 2025, Dr. Glickman reports direct ownership of 1,600 shares of common stock and no remaining derivative securities from this RSU grant.
enVVeno Medical Corp director Francis Duhay reported selling 4,900 shares of common stock on December 11, 2025 at a weighted-average price of $0.3556 per share. The sale was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573. After this transaction, the director beneficially owns 92,544 shares of enVVeno Medical common stock. The filing states that the trade was completed under a Rule 10b5-1 trading plan that the reporting person adopted in June 2025, which is a pre-arranged plan for trading company stock.
enVVeno Medical Corporation reported the results of its 2025 Annual Meeting of Stockholders. A total of 11,058,255 shares of common stock were represented in person or by proxy out of 20,216,176 shares outstanding and entitled to vote as of October 17, 2025, representing 54.70% of the voting power.
Stockholders voted on the election of two directors and several additional proposals. For the board seats, Matthew M. Jenusaitis received 3,468,484 votes for and 1,796,053 votes withheld, while Robert A. Berman received 4,727,591 votes for and 536,946 votes withheld. The filing also lists detailed vote totals for four other proposals, each showing the number of votes for, against, abstentions, and broker non-votes, providing transparency into stockholder participation and preferences.
enVVeno Medical Corporation is asking stockholders to approve authority for a reverse stock split of its common stock, at a ratio between one-for-five and one-for-thirty-five, to be implemented at the Board’s discretion if approved. The company currently has 20,216,176 shares outstanding; for example, at a one-for-five ratio this would become approximately 4,043,235 shares. The Board states its main goal is to lift the share price above Nasdaq’s $1.00 minimum bid requirement after receiving notice that the stock traded below that level for 30 consecutive business days, with a recent closing price of $0.3297 per share. The reverse split would not change authorized share counts, so it would increase the pool of authorized but unissued shares, and each holder’s ownership percentage is expected to remain about the same aside from fractional-share cashouts. The Board also reduced the quorum requirement for stockholder meetings to thirty three and one-third percent of voting shares outstanding.
enVVeno Medical Corporation (NVNO) disclosed that investor Thomas A. Satterfield, Jr. has filed a Schedule 13G reporting beneficial ownership of 1,822,500 shares of common stock, representing 9.0% of the outstanding shares, based on 20,216,176 shares outstanding as of October 28, 2025. Satterfield has sole voting and dispositive power over 165,000 shares and shared voting and dispositive power over 1,657,500 shares.
The filing explains that 400,000 shares are held through Tomsat Investment & Trading Co., Inc., wholly owned by Satterfield, and 1,250,000 shares are held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity in which he owns a 50% interest and serves as Chief Investment Manager. He certifies that the securities were not acquired for the purpose of changing or influencing control of enVVeno, indicating a passive investment stance.